Certolizumab pegol, sold under the brand name Cimzia, is a biopharmaceutical medication for the treatment of Crohn's disease,[4][5] rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
It is a fragment of a monoclonal antibody specific to tumor necrosis factor alpha (TNF-α) and is manufactured by UCB.
[6][7][2] It is on the World Health Organization's List of Essential Medicines.
[8] Certolizumab pegol is a monoclonal antibody directed against tumor necrosis factor alpha.
More precisely, it is a PEGylated Fab' fragment of a humanized TNF inhibitor monoclonal antibody.